Abstract

Ex vivo exposure of hematopoietic stem cells (HSCs) to 16,16-dimethyl PGE2 (FT1050) has been shown to enhance HSC engraftment potential in preclinical models. Several FT1050-dependent mechanisms may contribute to improved engraftment including increased proliferation, reduced apoptosis, and improved homing by upregulation of CXCR4. CXCR4 is the cell surface receptor for SDF-1, a chemokine that directs migration to the bone marrow niche. We have initiated clinical trials to evaluate whether FT1050 modulation improves outcomes for patients undergoing umbilical cord blood (UCB) transplantation.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.